NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2

HAEMATOLOGICA

Baliakas, P; Mattsson, M; Hadzidimitriou, A; Minga, E; Agathangelidis, A; Sutton, LA; Scarfo, L; Davis, Z; Yan, XJ; Plevova, K; Sandberg, Y; Vojdeman, FJ; Tzenou, T; Chu, CC; Veroneze, S; Mansouri, L; Smedby, KE; Giudicelli, V; Nguyen-Khac, F; Panagiotidis, P; Juliusson, G; Anagnostopoulos, A; Lefranc, MP; Trentin, L; Catherwood, M; Montillo, M; Niemann, CU; Langerak, AW; Pospisilova, S; Stavroyianni, N; Chiorazzi, N; Oscier, D; Jelinek, DF; Shanafelt, T; Darzentas, N; Belessi, C; Davi, F; Ghia, P; Rosenquist, R; Stamatopoulos, K, 2016: NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2. HAEMATOLOGICA 101, p. 231 - 231

Research Groups:

Medical Genomics

CEITEC authors:

Karla Plevová, Ph.D.
Prof. Šárka Pospíšilová, Ph.D.